The Routine Clinical use of Pharmacogenetic Tests: What it Will Require?
- PMID: 28236061
- DOI: 10.1007/s11095-017-2128-0
The Routine Clinical use of Pharmacogenetic Tests: What it Will Require?
Abstract
Pharmacogenetic testing aims to personalize drug therapy with a view to optimising drug efficacy and minimise toxicity. However, despite the potential benefits, pharmacogenetic testing is mostly confined to specialised medical areas, laboratories and centres. Widespread integration into routine clinical practice has been limited by a complex set of issues including regulatory and reimbursement frameworks, evidence of clinical utility and clinician perspectives, practices and education. Here we assess the current barriers to widespread clinical uptake and identify the key issue necessary to address to accelerate routine testing.
Keywords: biomarkers; clinical uptake; diagnostic tests; personalized medicine.
Similar articles
-
Individualizing pharmacogenomic test results in the context of the microbiome.Per Med. 2020 Nov;17(6):459-468. doi: 10.2217/pme-2020-0077. Epub 2020 Oct 7. Per Med. 2020. PMID: 33026284 Review.
-
The challenges of implementing pharmacogenomic testing in the clinic.Expert Rev Pharmacoecon Outcomes Res. 2017 Dec;17(6):567-577. doi: 10.1080/14737167.2017.1385395. Epub 2017 Oct 3. Expert Rev Pharmacoecon Outcomes Res. 2017. PMID: 28949250 Review.
-
Preemptive Panel-Based Pharmacogenetic Testing: The Time is Now.Pharm Res. 2017 Aug;34(8):1551-1555. doi: 10.1007/s11095-017-2163-x. Epub 2017 May 2. Pharm Res. 2017. PMID: 28466392 Free PMC article. Review.
-
Non-interventional cardiologists' perspectives on the role of pharmacogenomic testing in cardiovascular medicine.Per Med. 2019 Mar;16(2):123-132. doi: 10.2217/pme-2018-0099. Epub 2018 Dec 13. Per Med. 2019. PMID: 30543145
-
Facilitators and Barriers to the Adoption of Pharmacogenetic Testing in an Inner-City Population.Pharmacotherapy. 2018 Feb;38(2):205-216. doi: 10.1002/phar.2077. Epub 2018 Jan 21. Pharmacotherapy. 2018. PMID: 29286540
Cited by
-
Plasma extracellular nanovesicle (exosome)-derived biomarkers for drug metabolism pathways: a novel approach to characterize variability in drug exposure.Br J Clin Pharmacol. 2019 Jan;85(1):216-226. doi: 10.1111/bcp.13793. Epub 2018 Nov 16. Br J Clin Pharmacol. 2019. PMID: 30340248 Free PMC article.
-
Effect of Pharmacogenetic-Based Decision Support Tools in Improving Depression Outcomes: A Systematic Review.Neuropsychiatr Dis Treat. 2021 Jul 21;17:2397-2419. doi: 10.2147/NDT.S312966. eCollection 2021. Neuropsychiatr Dis Treat. 2021. PMID: 34321882 Free PMC article. Review.
-
The Role of Next-Generation Sequencing in Pharmacogenetics and Pharmacogenomics.Cold Spring Harb Perspect Med. 2019 Feb 1;9(2):a033027. doi: 10.1101/cshperspect.a033027. Cold Spring Harb Perspect Med. 2019. PMID: 29844222 Free PMC article. Review.
-
Pharmacogenomics Implementation and Hurdles to Overcome; In the Context of a Developing Country.Iran J Pharm Res. 2021 Fall;20(4):92-106. doi: 10.22037/ijpr.2021.114899.15091. Iran J Pharm Res. 2021. PMID: 35194431 Free PMC article.
-
Association of Pharmacogenotyping and Patient-Reported Outcomes in Chronic Pain Management.Health Serv Insights. 2025 Jul 12;18:11786329251356560. doi: 10.1177/11786329251356560. eCollection 2025. Health Serv Insights. 2025. PMID: 40655117 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources